Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-09-04
2010-02-23
Bowman, Amy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C514S04400A
Reexamination Certificate
active
07667030
ABSTRACT:
This invention relates to compounds, compositions, and methods useful for modulating matrix metalloproteinase (e.g., MMP13) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of MMP13 gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of MMP13 genes.
REFERENCES:
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 6346398 (2002-02-01), Pavco et al.
patent: 2003/0195164 (2003-10-01), Kahari et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2359180 (2000-03-01), None
patent: WO-90/014090 (1990-11-01), None
patent: WO-94/001550 (1994-01-01), None
patent: WO-99/032619 (1999-07-01), None
patent: WO-99/049029 (1999-09-01), None
patent: WO-00/044895 (2000-08-01), None
patent: WO-00/044914 (2000-08-01), None
patent: WO-01/036646 (2001-05-01), None
patent: WO-01/096584 (2001-12-01), None
patent: WO-01/096584 (2001-12-01), None
patent: WO-02/022636 (2002-03-01), None
patent: WO-02/044321 (2002-06-01), None
patent: WO-02/044321 (2002-06-01), None
patent: WO-03/064626 (2003-08-01), None
patent: WO-03/064626 (2003-08-01), None
Elbashir et al., Functional anatomy of siRNAs for mediating efficienct RNAi in Drosophila melanogaster embryo lysate, 2001, The Embo Journal, vol. 20, No. 23, pp. 6877-6888.
Parrish et al., Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference, 2000, Molecular Cell, vol. 6, pp. 1077-1087.
Bertrand et al., Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo, 2002, Biochemical and Biophysical Research Communications, 296, pp. 1000-1004.
Braasch et al., Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression, 2002, Biochemistry, vol. 41, No. 14, pp. 4503-4510.
Olie et al., Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide, 2002, Biochimica et Biophysica Acta, 1576, pp. 101-109.
Leeman et al., The structure, regulation, and function of human matrix metalloproteinase-13, Critical Reviews in Biochemistry and Molecular Biology, 2002, 37(3), pp. 149-166.
Anderson et al. “Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance,”Oligonucleotides13(5):303-312 (2003).
Bertrand et al. “Comparison of Antisense Oligonucleotides and siRNAs in Cell Culture and In Vivo,” Biochem. And Biophys. Res. Comm. 296:1000-1004 (2002).
Braasch et al. “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,” Biochem. 41:4503-4510 (2002).
Braasch et al. “RNA Interference in Mammalian Cells by Chemically-Modified RNA,”Biochem. 42:7967-7975 (2003).
Caplen “RNAi as a Gene Therapy Approach,”Expert Opin. Biol. Ther. 3(4):575-586 (2003).
Elbashir et al. “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs,”Methods26(2):199-213 (2002).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,”Nature411(6836):494-498 (2001).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate,”Embo J. 20(23):6877-6888 (2001).
Elbashir et al. “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,”Genes Dev. 15(2):188-200 (2001).
Fire et al. “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature391:806-811 (1998).
Futami et al. “Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against BcI-2,”Nucleic Acids Research Supplement2:251-252 (2002).
Hammond et al. “Post-Transcriptional Gene Silencing by Double-Straded RNA,” Nature 2:110-119 (2001).
International Search Report mailed on Mar. 31, 2005 for PCT/US04/16390, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05028, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05346, 1 page.
Kurreck et al. “Design of antisense oligonucleotides stabilized by Locked Nucleic Acids,”Nucl. Acids Res. 30(9):1911-1918 (2002).
Leeman et al. “The Structure, Regulation, and Function of Human Matrix Metalloproteinase-13,”Critical Reviews in Biochem. And Molec. Biol. 37(3):149-166 (2002).
Leirdal et al. “Gene Silencing in Mammalian Cells by Preformed Small RNA Duplexes,”Biochemical and Biophysical Research Communications295:744-748 (2002).
Lin et al. “A Novel mRNA-cDNA Interference Phenomenon for Silencing BcI-2 Expression in Human LNCaP Cells,”Biochemical and Biophysical Research Communications281:639-644 (2001).
Olie et al. “Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL Antisense Oligonucleotide,” Biochim. Biophys. Acta 1576:101-109 (2002).
Parrish et al. “Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference,” Mol. Cell 6:1077-1087 (2000).
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,”Molecular Interventions295(3):158-167 (2002).
Tuschl et al. “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,”Genes and Development13(24):3191-3197 (1999).
Zhang et al. “Single Processing Center Models for Human Dicer and Bacterial RNase III,” Cell 118:57-68 (2004).
Office Action mailed on Feb. 4, 2008 for U.S. Appl. No. 10/444,853, 37 pages.
Office Action mailed on Jul. 1, 2008 for U.S. Appl. No. 11/499,520, 13 pages.
Office Action mailed on Oct. 8, 2008 for U.S. Appl. No. 11/499,529, 34 pages.
Office Action mailed on Nov. 14, 2008 for U.S. Appl. No. 11/502,875, 14 pages.
Office Action mailed on Apr. 8, 2009 for U.S. Appl. No. 11/502,876, 31 pages.
Office Action mailed on Jan. 26, 2009 for U.S. Appl. No. 11/676,124, 15 pages.
Office Action mailed on Feb. 3, 2009 for U.S. Appl. No. 10/693,059, 7 pages.
Office Action mailed on Jul. 2, 2008 for U.S. Appl. No. 10/757,803, 26 pages.
Office Action mailed on Apr. 16, 2009 for U.S. Appl. No. 12/105,010, 24 pages.
Office Action mailed on Jul. 31, 2006 for U.S. Appl. No. 10/919,584, 19 pages.
Office Action mailed on Apr. 17, 2007 for U.S. Appl. No. 10/919,584, 8 pages.
Office Action mailed on Dec. 18, 2007 for U.S. Appl. No. 10/919,584, 41 pages.
Final Office Action mailed on Jul. 9, 2008 for U.S. Appl. No. 10/919,584, 36 pages.
Beigelman Leonid
McSwiggen James
Bowman Amy
Sirna Therapeutics, Inc.
Stracker Elaine C.
LandOfFree
RNA interference mediated inhibition of matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNA interference mediated inhibition of matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of matrix... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228205